In summary, metformin may suppress tumor growth by inhibiting PLC via GCDH/MRPL45‐mediated fatty acid oxidation and activating the cGMP‐PKG pathway, although this putative mechanism remains to be validated by further studies. The gene discussed is MRPL45; the disease is neoplasm.